Cargando…

Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study

Background: The fixed combination of extrafine beclometasone dipropionate 100 μg/formoterol 6 μg (extrafine BDP/F) delivered by NEXThaler has proved to be effective in patients with moderate-to-severe asthma in terms of lung function, symptoms and asthma control. The aim of this study was to investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bakakos, Petros, Chatziapostolou, Panagiotis, Katerelos, Panos, Efstathopoulos, Petros, Korkontzelou, Aliki, Katsaounou, Paraskevi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876660/ https://www.ncbi.nlm.nih.gov/pubmed/35207635 http://dx.doi.org/10.3390/jpm12020146

Ejemplares similares

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma
por: Ming, Simon Wan Yau, et al.
Publicado: (2019)

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
por: Corradi, Massimo, et al.
Publicado: (2016)

Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler(®) Device in Healthy Subjects, Asthmatic Patients, and COPD Patients
por: Virchow, Johann Christian, et al.
Publicado: (2018)

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
por: Skloot, Gwen S., et al.
Publicado: (2023)

Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study
por: Usmani, Omar S., et al.
Publicado: (2022)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)

2-Bromobeclometasone dipropionate
por: Ketuly, Kamal Aziz, et al.
Publicado: (2009)

Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial
por: O'Connor, Brian J, et al.
Publicado: (2011)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
por: Dean, James, et al.
Publicado: (2020)

9α-Bromo analog of beclometasone dipropionate monohydrate
por: Ketuly, Kamal Aziz, et al.
Publicado: (2009)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD
por: Chetta, Alfredo, et al.
Publicado: (2021)

Small Airways, Big Problem: Extrafine beclomethasone/formoterol in asthma and chronic obstructive pulmonary disease
por: Hasan, Ashfaq, et al.
Publicado: (2021)

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study
por: Singh, Dave, et al.
Publicado: (2017)

New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine
por: Paggiaro, Pierluigi
Publicado: (2009)

Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019)

Asthma: From Phenotypes to Personalized Medicine
por: Bakakos, Petros
Publicado: (2022)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

Unraveling the Relationship of Asthma and COVID-19
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

BDP/FF NEXThaler to Improve Asthma Control Status in the Real World: The NEWTON Study
por: Braido, Fulvio, et al.
Publicado: (2023)

Biological Therapy of Severe Asthma and Nasal Polyps
por: Bakakos, Agamemnon, et al.
Publicado: (2022)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine‐induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler
por: Singh, Dave, et al.
Publicado: (2019)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

The Effect of Smoking Cessation on Body Weight and Other Metabolic Parameters with Focus on People with Type 2 Diabetes Mellitus
por: Driva, Stamatina, et al.
Publicado: (2022)

Severe Asthma in the Era of Biologics: Continuous Challenges
por: Schoini, Pinelopi, et al.
Publicado: (2023)

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
por: Price, David, et al.
Publicado: (2013)

Epidemiology and Immunopathogenesis of Virus Associated Asthma Exacerbations
por: Bakakos, Agamemnon, et al.
Publicado: (2023)

Severe asthma: anti-IgE or anti-IL-5?
por: Papathanassiou, Evgenia, et al.
Publicado: (2016)

Identification of asthma phenotypes using blood cell count
por: Papaioannou, Andriana I, et al.
Publicado: (2022)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Fever and multilobular mass of the right lung in a young adult with asthma
por: Sotiriou, Adamantia, et al.
Publicado: (2015)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
por: Price, David B, et al.
Publicado: (2022)

11th Panhellenic Conference on Informatics
Publicado: (2007)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4tbarek3dkolourl3fht9nbe40